GoldenGolden
HotSpot Therapeutics

HotSpot Therapeutics

Biotechnology company developing medicines that target allosteric regulatory sites on proteins

HotSpot Therapeutics target regulatory mechanisms to create allosteric medicines such as small molecule molecules for treatment of autoimmune and rare diseases as well as cancer. The company’s SpotFinder technology platform is used to identify and target regulatory hotspots, a unique family of pockets situated remotely from the active site on a protein that are normally used in the body to control protein function. HotSpot’s lead compounds include allosteric inhibitors targeting PKC-theta for autoimmune diseases and S6 kinase involved in mitochondrial and metabolic function.

Timeline

April 14, 2021
HotSpot Therapeutics announces the appointment of industry leader, Timothy Reilly, as Chief Development Officer.
May 21, 2020
HotSpot Therapeutics raises a $65 million series B to fund development of allosteric medicines.
July 17, 2018
HotSpot Therapeutics raises a $45,000,000 series A round from Atlas.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
HotSpot Therapeutics Series A round, July 2018
45,000,000
July 17, 2018
1 Result
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Alex Keown
April 16, 2021
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
April 14, 2021
BioSpace
HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer - read this article along with other careers information, tips and advice on BioSpace
Alex Keown
November 20, 2020
BioSpace
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Alex Keown
May 21, 2020
BioSpace
Two years after Boston-based HotSpot Therapeutics launched, the company has secured $65 million in Series B funding to advance the development of its allosteric therapies that target "regulatory hotspots" in the body into the clinic.
Nick Paul
May 21, 2020
FierceBiotech
HotSpot Therapeutics has raised a $65 million series B to fund development of allosteric medicines. The financing, which was led by GlaxoSmithKline's SR One, positions HotSpot to move treatments for autoimmune disease and rare metabolic conditions into the clinic.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.